Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Lonza Group AG
  6. Summary
    LONN   CH0013841017

LONZA GROUP AG

(LONN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
09/20/2021 09/21/2021 09/22/2021 09/23/2021 09/24/2021 Date
748.4(c) 757(c) 757.4(c) 759.8(c) 742.6(c) Last
199 910 93 842 124 607 90 910 106 636 Volume
-0.58% +1.15% +0.05% +0.32% -2.26% Change
More quotes
Estimated financial data (e)
Sales 2021 5 151 M 5 569 M 5 569 M
Net income 2021 750 M 811 M 811 M
Net cash position 2021 314 M 340 M 340 M
P/E ratio 2021 74,0x
Yield 2021 0,41%
Sales 2022 5 851 M 6 327 M 6 327 M
Net income 2022 1 057 M 1 143 M 1 143 M
Net cash position 2022 236 M 255 M 255 M
P/E ratio 2022 51,9x
Yield 2022 0,45%
Capitalization 55 163 M 59 611 M 59 647 M
EV / Sales 2021 10,6x
EV / Sales 2022 9,39x
Nbr of Employees 14 405
Free-Float 99,7%
More Financials
Company
Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life science industries. The Company's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The Company divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. 
More about the company
Ratings of Lonza Group AG
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
A-
More Ratings
All news about LONZA GROUP AG
09/24LONZA : To Manufacture Allarity Therapeutics' Kidney Cancer Candidate Dovitinib
MT
09/23LONZA : Stifel Lifts Price Target on Lonza Group, Maintains Hold Recommendation
MT
09/23Allarity Therapeutics and Lonza Collaborates to Manufacture Dovitinib, a Renal Cell Car..
CI
09/22LONZA : to Invest in Expanding Drug Product Development Network in Switzerland
MT
09/22LONZA : Invests to Expand Drug Product Development and Manufacturing Services in Switzerla..
PU
09/21LONZA : Triumvira Begins Human Trials for T-Cell Cancer Therapy
MT
09/21Lonza and Triumvira Immunologics Announces First Patient with HER2-overexpressing Cance..
CI
09/13LONZA : Swiss Parliament Excluded from Federal Council's Vaccine Production Talks With Lon..
MT
08/26GLOBAL MARKETS LIVE : UMG, Delta Air Lines, Shiseido, Qantas, Lonza...
08/26LONZA : CFO to Move to Another Company; Novartis Executive to Take Over
MT
08/26Lonza Appoints New CFO
DJ
08/26LONZA : appoints Novartis executive as new Chief Financial Officer
RE
08/26LONZA : Philippe Deecke appointed as Chief Financial Officer of Lonza Group
PU
08/26LONZA : Names Novartis Exec as New CFO
MT
08/26EQS-ADHOC : Philippe Deecke appointed as Chief Financial Officer of Lonza Group
DJ
More news
News in other languages on LONZA GROUP AG
09/24Lonza va fabriquer le Dovitinib, le candidat d'Allarity Therapeutics pour le cancer du ..
09/23Lonza décroche un mandat du danois Allarity
09/23Lonza produziert Krebsmittel für Allarity Therapeutics
09/22Lonza va investir dans l'expansion du réseau de développement de produits pharmaceutiqu..
09/22Lonza investiert in der Schweiz und schafft 70 Arbeitsplätze
More news
Analyst Recommendations on LONZA GROUP AG
More recommendations
Chart LONZA GROUP AG
Duration : Period :
Lonza Group AG Technical Analysis Chart | LONN | CH0013841017 | MarketScreener
Technical analysis trends LONZA GROUP AG
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 742,60 CHF
Average target price 765,21 CHF
Spread / Average Target 3,05%
EPS Revisions
Managers and Directors
Pierre-Alain Ruffieux Chief Executive Officer
Rodolfo Savitzky Chief Financial Officer
Albert M. Baehny Chairman
Werner J. Bauer Independent Director
Barbara May Richmond No-Executive Independent Director
Sector and Competitors
1st jan.Capi. (M$)
LONZA GROUP AG30.56%59 611
MODERNA, INC.311.74%173 624
IQVIA HOLDINGS INC.46.01%50 128
CELLTRION, INC.-23.54%31 745
SEAGEN INC.-7.88%29 353
PHARMARON BEIJING CO., LTD.79.90%25 236